Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology

Figures & data

Figure 1. The dynamics of urinary symptoms (UrS) and quality of life (QoL) in 124 men with BPH after thermobalancing therapy and in the control group by the International Prostate Symptom Score (IPSS).

Figure 2. The changes in ultrasound prostate volume (PV) mL and uroflowmetry – Q_max mL/s parameters in 124 men with BPH after thermobalancing therapy & control group.

Table 1. Changes in prostate volume (PV, mL) and uroflowmetry (maximum urinary flow rate, Q_max, mL/s), and International Prostate Symptom Score (IPSS) for urinary symptoms (UrS) and quality of life (QoL), in men with BPH (PV >60 mL) upon thermobalancing therapy.

Changes in PV-mL, Qmax mL/s, and IPSS scores of UrS and QoL in men with BPH (PV >60 mL) after thermobalancing therapy
Patients	1	2	3	4	5
No Dates	1 July 2014– 3 November 2014	22 July 2014– 18 February 2015	3 February 2014– 3 November 2014	18 March 2014– 10 March 2015	31 March 2014– 24 March 2015
Age in years	73	79	75	73	77
IPSS – UrS	14–4	6–2	12–3	16.5–6	12.5–7
IPSS – QoL	4–1	3–1	4–0	14–4	4–3
PV, mL	93–70	154–90	84–52	74–51	110–88
Qmax, mL/s	11.2–14	13–14.4	9.7–15.5	7.2–10.3	5.8–6.8